Literature DB >> 22964431

The lymphotactin receptor is expressed in epithelial ovarian carcinoma and contributes to cell migration and proliferation.

Mijung Kim1, Lisa Rooper, Jia Xie, Jamie Rayahin, Joanna E Burdette, Andre A Kajdacsy-Balla, Maria V Barbolina.   

Abstract

Chemokine receptor-ligand interactions are important to support functioning of both normal and pathologic cells. The expression and function of chemokine receptors in epithelial ovarian carcinoma (EOC) is largely unknown. Here, we report that the lymphotactin receptor (XCR1) was expressed in primary and metastatic human epithelial ovarian carcinoma (EOC) specimens and cell lines. In contrast, expression of XCR1 was not detected in the normal ovary or in human normal ovarian surface epithelial cells. Our data indicate that XCL1 and XCL2 are either present in the malignant ascites or expressed by the ovarian carcinoma cells. The addition of lymphotactin (XCL1 and XCL2) stimulated migration and proliferation of XCR1-positive cells. Reduction of XCR1 expression in ovarian carcinoma cell line SKOV-3 resulted in abrogated diaphragm and peritoneal wall tumor formation and in reduced frequency of colonic, splenetic, and liver nodules in an in vivo xenograft mouse model. Taken together, our data suggest that XCR1 is expressed early during the course of tumorigenic transformation and contributes towards increased cell migration and proliferation, which can facilitate the prometastatic behavior of EOC cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964431     DOI: 10.1158/1541-7786.MCR-12-0361

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  25 in total

Review 1.  Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwendlyn Kollmorgen; Rüdiger Rueger
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

2.  Structural and agonist properties of XCL2, the other member of the C-chemokine subfamily.

Authors:  Jamie C Fox; Takashi Nakayama; Robert C Tyler; Tara L Sander; Osamu Yoshie; Brian F Volkman
Journal:  Cytokine       Date:  2014-12-11       Impact factor: 3.861

Review 3.  Molecular mechanisms and clinical management of cancer bone metastasis.

Authors:  Manni Wang; Fan Xia; Yuquan Wei; Xiawei Wei
Journal:  Bone Res       Date:  2020-07-29       Impact factor: 13.567

4.  Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.

Authors:  Hilal Gurler; Yi Yu; Jacqueline Choi; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Int J Mol Sci       Date:  2015-02-04       Impact factor: 5.923

Review 5.  Transcriptional regulation of chemokine expression in ovarian cancer.

Authors:  Bipradeb Singha; Himavanth R Gatla; Ivana Vancurova
Journal:  Biomolecules       Date:  2015-03-17

Review 6.  Role of Chemokines in Non-Small Cell Lung Cancer: Angiogenesis and Inflammation.

Authors:  Selma Rivas-Fuentes; Alfonso Salgado-Aguayo; Silvana Pertuz Belloso; Patricia Gorocica Rosete; Noé Alvarado-Vásquez; Guillermo Aquino-Jarquin
Journal:  J Cancer       Date:  2015-08-07       Impact factor: 4.207

7.  Fractalkine receptor is expressed in mature ovarian teratomas and required for epidermal lineage differentiation.

Authors:  Lisa Rooper; Hilal Gurler; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  J Ovarian Res       Date:  2013-08-17       Impact factor: 4.234

8.  An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.

Authors:  Christina Yau; John Sninsky; Shirley Kwok; Alice Wang; Amy Degnim; James N Ingle; Cheryl Gillett; Andrew Tutt; Fred Waldman; Dan Moore; Laura Esserman; Christopher C Benz
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

Review 9.  Chemokine receptors in epithelial ovarian cancer.

Authors:  Goda G Muralidhar; Maria V Barbolina
Journal:  Int J Mol Sci       Date:  2013-12-31       Impact factor: 5.923

10.  Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids.

Authors:  Mark Desjardins; Jia Xie; Hilal Gurler; Goda G Muralidhar; Joelle D Sacks; Joanna E Burdette; Maria V Barbolina
Journal:  J Ovarian Res       Date:  2014-06-26       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.